Beyond The Printed Page

  1. Making A Difference For Mothers And Merck

    In 2011, Merck undertook a big corporate social responsibility (CSR) initiative — Merck for Mothers. According to Priya Agrawal, the program’s executive director, the $500 million dollar 10-year program was driven from the senior-most Merck leadership.

  2. Biopharma Trendsetter Jeremy Levin Weighs In On What To Anticipate For 2016: Trendsetter Series Part 4 of 4

    When we asked Jeremy Levin, former CEO of Teva Pharmaceuticals, “What’s going to be big in biopharma in 2016,” you get a very different and global biopharma industry perspective. When you combine leading a generic powerhouse, Levin’s strategic alliance experience at Novartis and Bristol-Myers Squibb with the insights gathered from serving in the current role as chairman and CEO, Ovid Therapeutics, a pure play neurology company, you get significant experience and insight.

  3. The 2016 Trends Novartis U.S. President Christi Shaw Is Closely Watching: Trendsetter Series Part 3 of 4

    In our Trendsetter series, Christi Shaw, US Country Head, president of Novartis Corporation & president of Novartis Pharmaceuticals Corporation, gives her previously unpublished thoughts as to what key trends Shaw is intent on keeping her eyes on for 2016.

  4. Purdue Pharma CEO Mark Timney Reveals Key Trends For 2016: Trendsetter Series Part 2 of 4

    In Life Science Leader magazine’s 2016 Trendsetter Series, there was too much good content to fit on all the printed pages. To eliminate the possibility of not sharing all of the executives’ comprehensive insights, we created a series of online articles as a supplement to the feature, What Nine Of Biopharma’s Biggest Trendsetters Expect For 2016? Mark Timney, Purdue Pharma’s CEO gives his insights on global macro trends and nontraditional companies he thinks will impact biopharma.

  5. What The CEO of OncoMed Pharmaceuticals Expects For 2016: Trendsetter Series Part 1 of 4

    The first trendsetter of our four-part series is Paul Hastings, chairman and CEO of OncoMed Pharmaceuticals. A seasoned executive with experience spanning the likes of QLT, Axys Pharmaceuticals, Chiron BioPharmaceuticals, LXR Biotechnology, and Genzyme, the following are Hastings’ previously unpublished responses to trends from other industries that will be big for biopharma for 2016.

  6. Why A Formally Trained Pediatrician Decided To Join the FDA

    “My professional training is as a pediatrician,” says the FDA’s director of the Office of Biotechnology Products, Steven Kozlowski, M.D.

  7. Leadership By Walking Around

    Leadership by walking around may sound like an antiquated philosophy, but for FDA’s Office of Biotechnology Products director, Steven Kozlowski, M.D. it's a best practice that is part of his exercise routine.

  8. Warning: Cancer Immunotherapy Information

    If you can say that you completely understand how immunotherapy works in cancer, please feel free to skip this small primer. But for the vast crowd that constitutes the rest of us, we include this basic explanation. 

  9. Immuno-Oncology — The Year’s News In Science

    In 2014, many of the most encouraging studies of checkpoint blockade went public at the annual ASCO (American Society of Clinical Oncology) meeting. This year, even more positive studies of new checkpoint inhibitors were reported.

  10. Combo Immuno-Oncology R&D Programs — Recent & Ongoing

    By careful estimate, companies will have a large number of combination cancer immunotherapy trials in planning or execution as of Jan. 1, 2016.